KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Nektar Therapeutics (NKTR) Accumulated Depreciation & Amortization (2016 - 2024)

Nektar Therapeutics (NKTR) has 10 years of Accumulated Depreciation & Amortization data on record, last reported at $4.1 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization fell 41.43% year-over-year to $4.1 million; the TTM value through Dec 2024 reached $4.1 million, down 41.43%, while the annual FY2024 figure was $4.1 million, 41.43% down from the prior year.
  • Accumulated Depreciation & Amortization reached $4.1 million in Q4 2024 per NKTR's latest filing, down from $7.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $13.0 million in Q4 2021 and bottomed at -$32.5 million in Q2 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $2.7 million, with a median of $9.6 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 13.64% in 2020, then crashed 42.62% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $12.5 million in 2020, then rose by 4.0% to $13.0 million in 2021, then fell by 6.15% to $12.2 million in 2022, then crashed by 42.62% to $7.0 million in 2023, then crashed by 41.43% to $4.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $4.1 million in Q4 2024, $7.0 million in Q4 2023, and $12.2 million in Q4 2022.